JNJ

230.49

+2.4%↑

UNH

366.37

-0.47%↓

TMO

470.56

+0.12%↑

ISRG

450.54

-0.34%↓

ABT

90.55

-2%↓

JNJ

230.49

+2.4%↑

UNH

366.37

-0.47%↓

TMO

470.56

+0.12%↑

ISRG

450.54

-0.34%↓

ABT

90.55

-2%↓

JNJ

230.49

+2.4%↑

UNH

366.37

-0.47%↓

TMO

470.56

+0.12%↑

ISRG

450.54

-0.34%↓

ABT

90.55

-2%↓

JNJ

230.49

+2.4%↑

UNH

366.37

-0.47%↓

TMO

470.56

+0.12%↑

ISRG

450.54

-0.34%↓

ABT

90.55

-2%↓

JNJ

230.49

+2.4%↑

UNH

366.37

-0.47%↓

TMO

470.56

+0.12%↑

ISRG

450.54

-0.34%↓

ABT

90.55

-2%↓

Search

Quanterix Corp

Închisă

SectorSănătate

3.15 -2.48

Rezumat

Modificarea prețului

24h

Curent

Minim

2.95

Maxim

3.22

Indicatori cheie

By Trading Economics

Venit

10M

-23M

Vânzări

3.7M

44M

Marjă de profit

-52.712

Angajați

450

EBITDA

15M

-17M

Recomandări

By TipRanks

Recomandări

Neutru

Prognoză pe 12 luni

+80.33% upside

Dividende

By Dow Jones

Următoarele câștiguri

6 mai 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-145M

151M

Deschiderea anterioară

5.63

Închiderea anterioară

3.15

Sentimentul știrilor

By Acuity

15%

85%

27 / 348 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Neutral Evidence

Quanterix Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

29 apr. 2026, 23:53 UTC

Câștiguri

Naver Posts Weaker First-Quarter Earnings

29 apr. 2026, 23:41 UTC

Acțiuni populare

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29 apr. 2026, 23:55 UTC

Câștiguri

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29 apr. 2026, 23:54 UTC

Câștiguri

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29 apr. 2026, 23:52 UTC

Câștiguri

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29 apr. 2026, 23:51 UTC

Câștiguri

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29 apr. 2026, 23:51 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29 apr. 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29 apr. 2026, 23:24 UTC

Câștiguri

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29 apr. 2026, 23:24 UTC

Câștiguri

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29 apr. 2026, 23:24 UTC

Câștiguri

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29 apr. 2026, 23:24 UTC

Câștiguri

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29 apr. 2026, 23:22 UTC

Câștiguri

China Longyuan 1Q Net CNY1.70B, Down 14%

29 apr. 2026, 23:22 UTC

Câștiguri

China Longyuan: Power Generation Down 2.9% as of End-March

29 apr. 2026, 23:20 UTC

Câștiguri

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29 apr. 2026, 23:20 UTC

Câștiguri

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29 apr. 2026, 23:19 UTC

Câștiguri

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29 apr. 2026, 23:19 UTC

Câștiguri

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29 apr. 2026, 23:19 UTC

Câștiguri

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29 apr. 2026, 23:19 UTC

Câștiguri

China Vanke 1Q Loss Narrows>000002.SZ

29 apr. 2026, 23:18 UTC

Câștiguri

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29 apr. 2026, 23:17 UTC

Câștiguri

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29 apr. 2026, 23:15 UTC

Câștiguri

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29 apr. 2026, 23:15 UTC

Câștiguri

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29 apr. 2026, 23:13 UTC

Câștiguri

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29 apr. 2026, 23:12 UTC

Câștiguri

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29 apr. 2026, 23:11 UTC

Câștiguri

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29 apr. 2026, 23:11 UTC

Câștiguri

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29 apr. 2026, 23:04 UTC

Câștiguri

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29 apr. 2026, 23:04 UTC

Câștiguri

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Comparație

Modificare preț

Quanterix Corp Așteptări

Obiectiv de preț

By TipRanks

80.33% sus

Prognoză pe 12 luni

Medie 5.5 USD  80.33%

Maxim 7 USD

Minim 4 USD

În baza a 2 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruQuanterix Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

2 ratings

0

Cumpărare

2

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

5.34 / 6.015Suport & Rezistență

Termen scurt

Neutral Evidence

Termen mediu

Bullish Evidence

Termen lung

No Evidence

Sentiment

By Acuity

27 / 348 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Quanterix Corp

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.
help-icon Live chat